Evaluation of a peripheral vein for intravenous chemotherapy: a prospective observational study
Abstract
This study aimed to assess over time alterations of a peripheral vein used for chemotherapy infusion in patients with breast cancer. It is a prospective observational study which included patients who were scheduled to receive peripheral infusion of chemotherapy. These patients had the first peripheral vein used for infusion evaluated in five moments: before the venipuncture, after device removal at the end of the first chemotherapy infusion, and on days 21, 42, and 63 after the first infusion. The primary outcome was the caliber of the vein, measured in millimeters with a Veinlite LEDX® transilluminator and a tape measure. Fifty-nine women receiving doxorubicin and docetaxel for the first time were enrolled to the study. The caliber size varied from 2 to 4 millimeters at baseline, and decreased overtime. During the follow-up period, peripheral veins of 35 women (59.3%) were measured at 0 mm at day 63. The remaining 24 women (40.7%) had some recovery, but for 15 of them (62.5%) the vein became a palpable cord. The feasibility of using a peripheral vein to perform chemotherapy decreased as the treatment progresses.
Downloads
References
Bertoglio S, Boxtel TV, Goossens GA, Dougherty L, Furtwangle R, Lennan E, et al. Mejora de los resultados del acceso vascular periférico corto en la administración de oncología y quimioterapia. J Vasc Access. 2017;18(2), 89-96. Disponible en: https://doi.org/10.5301%2Fjva.5000668
Reis PED, Rodrigues CC, Vasques CI, Carvalho EC. Efectos adversos por Drogas quimioterápicas identificados en el sitio de infusión intravenosa periférica. Ciencia y Enfermeria. 2008;14(2), 55-64.
McGowan D, Wood S. Desarrollando una herramienta de evaluación venosa en la administración de quimioterapia intravenosa. Br J Nurs. 2008;17(3), 158-164. Disponible en: https://doi.org/10.12968/bjon.2008.17.3.28404
Cole T. Riesgos y beneficios del uso de agujas en pacientes después de una cirugía de ganglios axilares. Br J Nurs. 2006;15(18), 969-979. Disponible en: https://doi.org/10.12968/bjon.2006.15.18.22020
García-Mata J, García-Palomo A, Calvo L, Mel R, Cruz JJ, Ramos M. Estudio de fase II de doxorrubicina densa en dosis y docetaxel como quimioterapia neoadyuvante con apoyo de G-CSF en pacientes con cáncer de mama grande o localmente avanzado. Clin Transl Oncol. 2008;10(11), 739-744. Disponible en: https://doi.org/10.1007/s12094-008-0280-z
Montañez-Valverde RA, Hurtado-de-Mendoza D, Loaiza-Bonilla A. Cardiotoxicidad: Miocardio o Endotelio. Cureus. 2018;10(7), e2994. Disponible en: https://doi.org/10.7759/cureus.2994
Cameron AC, Touyz RM, Lang NN. Complicaciones vasculares de la quimioterapia contra el cáncer. Can J Cardiol. 2016;32(7), 852-862. Disponible en: https://doi.org/10.1016/j.cjca.2015.12.023
Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos MA, et al. Toxicidad vascular endotelial por agentes quimioterapéuticos: evidencia preclínica e implicaciones clínicas. Cancer Treat Rev. 2012;38(5), 473-483. Disponible en: https://doi.org/10.1016/j.ctrv.2011.09.002
Wojcik T, Szczesny E, Chlopicki S. Efectos perjudiciales de la quimioterapia y otros fármacos en el endotelio: un llamado a la elaboración de perfiles de toxicidad endotelial. Pharmacol Rep. 2015;67(4), 811-817.
Mestre G, Berbel C, Tortajada P, Alarcia M, Coca R, Fernández MM, et al. Intervención multifacética exitosa dirigida a reducir los eventos adversos relacionados con el catéter venoso periférico corto: un estudio de cohorte cuasi experimental. Am J Infect Control. 2013; 41(6), 520-526. Disponible en: https://doi.org/10.1016/j.ajic.2012.07.014
Alexandrou E, Ray-Barruel G, Carr PJ, Frost S, Inwood S, Higgins N, et al. Prevalencia internacional del uso de catéteres intravenosos periféricos. J Hosp Med. 2015; 10(8), 530-533. Disponible en: https://doi.org/10.1002/jhm.2389
Atay S, Sen S, Cukurlu D. Cateterismo venoso periférico relacionado con la flebitis y los factores de riesgo asociados. Niger J Clin Pract. 2018; 21(7), 827-831. Disponible en: https://doi.org/10.4103/njcp.njcp_337_17
Schulmeister L. Manejo de extravasación: actualización clínica. Semin Oncol Nurs. 2011; 27(1), 82-90. Disponible en: https://doi.org/10.1016/j.soncn.2010.11.010
Sakaida E, Sekine I, Iwasawa S, Kurimoto R, Uehara T, Ooka Y, et al. Incidencia, factores de riesgo y resultados del tratamiento de la extravasación de agentes citotóxicos en una clínica de quimioterapia para pacientes ambulatorios. Jpn J Clin Oncol. 2014; 44(2), 168-171. Disponible en: https://doi.org/10.1093/jjco/hyt186
Gallieni M, Pittiruti M, Biffi R. Acceso vascular en pacientes oncológicos. CA: Cancer J Clin. 2008; 58(6), 323-346. Disponible en: https://doi.org/10.3322/ca.2008.0015
Gorski L, Hadaway L, Hagle ME, McGoldrick M, Orr M, Doellman D. Estándares de práctica de la terapia de infusión. J Infus Nurs, 2016; 39(1S), 1-169. Disponible en: https://doi.org/10.1097/nhh.0000000000000481
The works published in this magazine are subject to the following terms:
1. The Publications Service of the University of Murcia (the publisher) preserves the copyright of the published works, and encourages and allows the reuse of the works under the license for use stated in point 2.
© Servicio de Publicaciones, Universidad de Murcia, 2011 (© Publications Service, University of Murcia, 2011)
2. The works are published in the electronic edition of the journal under Creative Commons Reconocimiento-NoComercial-SinObraDerivada 3.0 España(texto legal) “ a Attribution-NonCommercial-NoDerivatives 3.0 Spain license (legal text)”. They can be copied, used, broadcasted, transmitted and publicly displayed, provided that: i) the authorship and original source of their publication (journal, publisher and URL) are cited; (ii) are not used for commercial purposes; iii) the existence and specifications of this license is mentioned.
3. Conditions of self-archiving. Authors are allowed and encouraged to electronically disseminate the pre-print (pre-reviewed ) and / or post-print (reviewed and accepted for publication) versions of their works prior to publication, as it ensures a wider circulation and dissemination which may lead to a possible increase in its mention and a higher scope among the academic community. RoMEO color: green.
